Gemtesa, also known as vibegron, is a medication approved for the treatment of overactive bladder (OAB) with or without urinary incontinence, urgency, and frequency. In Mexico, Gemtesa is available in a 75 mg dosage.
What is Gemtesa 75 mg used for in Mexico?
Gemtesa 75 mg in Mexico is prescribed to adults diagnosed with overactive bladder. This condition is characterized by sudden, strong urges to urinate, often accompanied by involuntary urine leakage (urge incontinence), and a frequent need to urinate [1].
How does Gemtesa 75 mg work?
Vibegron, the active ingredient in Gemtesa, is a selective beta-3 adrenergic agonist. It works by relaxing the detrusor smooth muscle in the bladder. This relaxation increases bladder capacity and reduces the frequency and urgency of urination associated with OAB [1].
When did Gemtesa become available in Mexico?
Information regarding the specific launch date of Gemtesa 75 mg in Mexico is not readily available. However, the drug has received approval in various global markets, indicating its availability for treating OAB.
What are the potential side effects of Gemtesa 75 mg?
Common side effects of Gemtesa may include headache, nasopharyngitis (common cold), diarrhea, nausea, and upper respiratory tract infections. Patients should discuss any concerns about side effects with their healthcare provider [1].
How does Gemtesa 75 mg compare to other OAB treatments?
Gemtesa offers a different mechanism of action compared to other OAB treatments. For example, anticholinergics work by blocking acetylcholine, which can cause bladder muscle contractions. Gemtesa's beta-3 agonist action directly targets bladder muscle relaxation. The choice of treatment depends on individual patient needs, medical history, and potential side effects.
Who manufactures Gemtesa 75 mg?
Gemtesa was developed by Urovant Sciences. In Mexico, it may be marketed by Urovant Sciences or a local pharmaceutical partner.
What is the patent status of Gemtesa?
Drug patents play a significant role in the exclusivity and pricing of medications. Information on Gemtesa's patent status in Mexico can be found through resources like DrugPatentWatch.com, which tracks patent expirations and can indicate when generic versions might become available [2].
Sources:
1. Gemtesa. https://www.gemtesa.com/
2. DrugPatentWatch.com. https://drugpatentwatch.com/